Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression.
Mycobacterium tuberculosis accelerates the progression of human immunodeficiency virus type 1 (HIV-1) infection. The results of this study, which show that thalidomide inhibits the upregulation of HIV-1 expression in U1 cells stimulated with mycobacterial lipoarabinomannans, support the rationale behind conducting controlled trials of this immunodeficiency agent with patients dually infected with HIV-1 and M. tuberculosis.
Peterson
P K
PK
Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA.
Gekker
G
G
Bornemann
M
M
Chatterjee
D
D
Chao
C C
CC
D002999:Clone Cells; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology; D009169:Mycobacterium tuberculosis / Q000737:chemistry*; D013792:Thalidomide / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects; D014779:Virus Replication
D008070:Lipopolysaccharides; C050016:lipoarabinomannan; D013792:Thalidomide